Skip to main content
. 2015 Nov 12;7(3):386–395. doi: 10.1111/jdi.12430

Figure 1.

Figure 1

Changes in body mass index (BMI), hemoglobin A1c (HbA1c) and the HbA1c target rate after the start of metformin (Met), dipeptidyl peptidase‐4 inhibitor (DPP‐4i) and sulfonylurea (SU) treatment. The changes in (a) BMI, (b) HbA1c, and (c) the achievement rate of HbA1c <7.0% (black column) and <7.5% (gray column) in all patients are shown. The figures for the mean decline in BMI, ΔBMI and the mean decline in HbA1c, ΔHbA1c, which were calculated by subtracting the each value 3, 6, 9 and 12 months after the initiation of drug from the value at the initiation time, are inserted in each figure. The changes in (d) BMI, (e) HbA1c and (f) the achievement rate of HbA1c <7.0% (black column) and <7.5% (gray column) in the patients selected by means of propensity score matching for the following characteristics: age, age‐of‐onset, duration of diabetes, body mass index, systolic and diastolic blood pressure, post‐prandial plasma glucose, hemoglobin A1c, total cholesterol, lowdensity lipoprotein cholesterol and triglyceride are shown. Statistical analyses were carried out using one‐way analysis of variance (anova), a Tukey's honest significant difference and the Fisher's exact test.